| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10.09. | Voyageur Pharmaceuticals Ltd.: (PODCAST) Voyageur Pharmaceuticals (TSXV:VM) Achieves First Milestone in Bayer Collaboration, Secures USD $1 Million Payment | 26 | TheNewswire | ||
| VOYAGEUR PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 09.09. | Voyageur Pharmaceuticals Ltd: Voyageur Pharma receives $1M (U.S.) payment from Bayer | 16 | Stockwatch | ||
| 09.09. | Voyageur Pharmaceuticals Ltd.: Voyageur Pharmaceuticals Achieves First Milestone on Feasibility Study for Iodine Production; Secures USD $1 Million Payment | 1 | TheNewswire | ||
| 10.08. | Voyageur Pharmaceuticals Ltd: Voyageur posts 99.8% iodine purity in lab tests | 1 | Stockwatch | ||
| 10.08. | Voyageur Pharmaceuticals Ltd.: Voyageur Pharmaceuticals Advances Mueller Iodine Extraction Process with 99.8% Purity Results and Planned Field Pilot Testing | 3 | TheNewswire | ||
| 17.07. | Voyageur Pharmaceuticals Ltd: Voyageur hires Red Cloud for market-making | 1 | Stockwatch | ||
| 17.07. | Voyageur Pharmaceuticals Ltd.: Voyageur Pharmaceuticals Announces the Engagement of Red Cloud Securities as Market Maker | 1.088 | Newsfile | Calgary, Alberta--(Newsfile Corp. - July 17, 2026) - Voyageur Pharmaceuticals Ltd. (TSXV: VM) (OTC Pink: VYYRF) ("Voyageur" or the "Company"), a Canadian developer of pharmaceutical-grade barium... ► Artikel lesen | |
| 16.07. | Voyageur Pharmaceuticals Ltd: Voyageur Pharmaceuticals private placement | 1 | Stockwatch | ||
| 23.06. | Voyageur Pharmaceuticals Ltd.: Voyageur Pharmaceuticals Engages Fluor to Advance Feasibility Studies for Iodine Production and Integrated Contrast Drug Manufacturing Facility | 5 | TheNewswire | ||
| 18.06. | Voyageur Pharmaceuticals Ltd.: Voyageur Pharmaceuticals Evaluating Three Locations in the United States for Integrated Iodine and Barium Contrast Media Manufacturing Facility, a Multi-Phase Investment Expected to Generate Significant Economic Impact and H | 2 | TheNewswire | ||
| 10.06. | Voyageur Pharmaceuticals Ltd: Voyageur submits exploration permit application for FC | 1 | Stockwatch | ||
| 10.06. | Voyageur Pharmaceuticals Ltd. Submits Multi-Year Area-Based Exploration Permit Application for Bulk Sampling and Feasibility Support at Frances Creek Barite Project | 1 | TheNewswire | ||
| 06.06. | Voyageur Pharmaceuticals Ltd: Voyageur Pharmaceuticals closes $5M private placement | 1 | Stockwatch | ||
| 06.06. | Voyageur Pharmaceuticals Ltd.: Voyageur Announces Closing Of Non-Brokered Private Placement Pursuant To Listed Issuer Financing Exemption | 1 | TheNewswire | ||
| 28.05. | Voyageur Pharmaceuticals Ltd.: Voyageur Announces Filing Of Amended And Restated Offering Document | 3 | TheNewswire | ||
| 02.05. | Voyageur Pharmaceuticals Ltd.: Voyageur Announces Update To Non-Brokered Life Offering | 1 | TheNewswire | ||
| 17.04. | Voyageur Pharmaceuticals Ltd: Voyageur completes $100,000 shares for debt deal | 1 | Stockwatch | ||
| 17.04. | Voyageur Pharmaceuticals Ltd.: Voyageur Announces Shares for Debt Settlement and Stock Option Repricing | 2 | TheNewswire | ||
| 02.04. | Voyageur Pharmaceuticals Ltd: Voyageur Pharmaceuticals 888,888 units for debt | 1 | Stockwatch | ||
| 25.03. | Voyageur Pharmaceuticals Ltd: Voyageur arranges $7.5-million private placement | 1 | Stockwatch |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 49,310 | 0,00 % | Aktie steigt: Bayer macht Kasse: Dieser Pharma-Deal bringt bis zu 375 Millionen Euro | © Foto: Juan Vega - EUROPA PRESSBayer verkauft Stivarga für bis zu 375 Millionen Euro an Grünenthal, stärkt damit seine Bilanz und treibt den Umbau der Pharmasparte weiter voran Enthaltene Werte: DE000BAY0017Den... ► Artikel lesen | |
| JAGUAR HEALTH | 9,010 | +1,12 % | XFRA NEW INSTRUMENTS AVAILABLE ON 17.09.2026 | The following instruments on XETRA do have their first trading 17.09.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 17.09.2026
Aktien
1 CNE100007DY4 Shenzhen Woer Heat-Shrinkable... ► Artikel lesen | |
| MERCK KGAA | 133,30 | +0,26 % | Community-Rückblick: "Moderna wäre um min. 50% gestiegen, BioNTech bisher nicht mal 2%. That's it!" | © Foto: Julia Cebella - dpaNeue Onkologie-Daten sorgen bei BioNTech für Diskussionen: Warum reagiert die Aktie trotz guter Studienergebnisse kaum? Die wO User Diskutieren über Pipeline, Bewertung und... ► Artikel lesen | |
| NOVO NORDISK | 33,310 | -1,58 % | Token-Aktien im Aufwind: Coinbase: SEC schiebt Aktie an | Novo: Unter Druck | Siemens: Robotikfantasie | Humanoide Roboter gehen in die Massenproduktion: Ubtech plant mehr als 10.000 Stück pro Jahr. Siemens liefert die digitale Fabrik dahinter - und könnte so zum stillen Gewinner des Robotik-Booms werden.SEC... ► Artikel lesen | |
| GENERATE BIOMEDICINES | 16,505 | -0,09 % | Generate Biomedicines auf dem Bernstein Healthcare Forum: Daten statt Modelle | ||
| APNIMED | 22,500 | 0,00 % | Apnimed, Inc.: Apnimed Reports Second Quarter 2026 Financial Results and Provides Corporate Update | U.S. Food and Drug Administration ("FDA") Accepted the NDA for AD109, with a proposed proprietary name Oxnimbi- and assigned a PDUFA target action date of February 28,- 2027 If approved, Oxnimbi... ► Artikel lesen | |
| ETON PHARMACEUTICALS | 55,62 | 0,00 % | Biotech Stocks At 52-Week Highs - Eton Pharmaceuticals +44%, DexCom, Oruka Therapeutics, Concentra Group Holdings Parent, AtaiBeckley | INDIANAPOLIS (dpa-AFX) - The following biotech stocks reached 52-week highs on August 14, 2026, following positive quarterly reports or an announced upcoming acquisition. Eton Pharmaceuticals... ► Artikel lesen | |
| LB PHARMACEUTICALS | 39,160 | 0,00 % | LB Pharmaceuticals auf TD Cowen Summit: Wirkstoffkandidat LB-102 zielt auf sicherere psychiatrische Behandlungen ab | ||
| SEAPORT THERAPEUTICS | 21,290 | 0,00 % | Seaport Therapeutics: Wirkstoff-Pipeline gewinnt an Dynamik | ||
| KARDIGAN | 14,510 | -0,07 % | Citi's U.S. Consumer Cards Business To Buy Kard Financial For Undisclosed Terms | WASHINGTON (dpa-AFX) - Banking major Citigroup Inc. (C) announced late Thursday that its U.S. Consumer Cards business has agreed to acquire Kard Financial, a commerce media and rewards platform.... ► Artikel lesen | |
| ELI LILLY | 1.017,20 | +0,51 % | Novo-Medikament Cagrisema in Studie besser als Lilly-Konkurrenzprodukt | DJ Novo-Medikament Cagrisema in Studie besser als Lilly-Konkurrenzprodukt
Von Elias Schisgall
DOW JONES--Novo Nordisk hat einen Studienerfolg mit seinem Abnehm- und Typ-2-Diabetesmedikament... ► Artikel lesen | |
| OMNIAB | 4,780 | -0,21 % | Veraxa Biotech AG: VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb | VXA-222 advances into next phase at VERAXAZURICH, SWITZERLAND, July 27, 2026 --
VERAXA Biotech AG (NASDAQ: VRXA; "VERAXA" or the "Company"), an emerging leader in designing novel cancer therapies... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 4,700 | 0,00 % | Aquestive Therapeutics, Inc.: Aquestive Therapeutics Announces Resubmission of New Drug Application to FDA for Anaphylm (dibutepinephrine) Sublingual Film | Resubmission supported by positive topline human factors and pharmacokinetic (PK) study results announced in August 2026FDA will determine the resubmission classification and establish the applicable... ► Artikel lesen | |
| SCHOTT PHARMA | 24,100 | +1,26 % | Aktien Frankfurt: Dax macht Verluste wett - Ölpreis und Anleiherenditen im Fokus | FRANKFURT (dpa-AFX) - Der deutsche Aktienmarkt hat sich am Dienstagnachmittag von seinen Anfangsverlusten vollständig erholt. Eine leichte Entspannung bei den Ölpreisen und bei den Anleiherenditen... ► Artikel lesen | |
| TRISALUS LIFE SCIENCES | 4,970 | -0,60 % | TriSalus Secures FDA Clearance For TriNav Advance as Stock Tests Key Support |